A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

NCT07733180 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Esophageal Squamous Cell Carcinoma
Metastatic Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Tislelizumab
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: 5-fluorouracil (5-FU)

Sponsor

BeOne Medicines